Clinical Trial

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with Antitumor Therapy in Advanced Urothelial Carcinoma. To explore the reasonable dosage of SHR-A2102 for Advanced Urothelial Carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-10.
Status change: Not Yet Recruiting → Recruiting 2024-11-15
Trial Details
NCT Number NCT06639347
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced Urothelial Carcinoma
Enrollment 90 participants
Start Date 2024-11-04
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-18